Adaptive Biotechnologies (ADPT) Receivables - Other (2018 - 2026)

Adaptive Biotechnologies has reported Receivables - Other for 9 years, with the latest figure at $1.6 million in Q1 2026.

• Quarterly Receivables - Other rose 6.67% year-over-year to $1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (up 6.67% YoY) and the FY2025 annual result came in at $1.5 million, up 15.38% from the prior year.
• Receivables - Other improved to $1.6 million in Q1 2026 per ADPT's latest filing, from $1.5 million in the prior quarter.
• Over five years, Receivables - Other peaked at $1.6 million in Q1 2026 and troughed at $800000.0 in Q2 2022.
• A 5-year average of $1.2 million and a median of $1.1 million in 2022 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2022 and 2025: Receivables - Other tumbled 65.22% in 2022, then surged 36.36% in 2025.
• Over 5 years, Receivables - Other stood at $800000.0 in 2022, then climbed by 25.0% to $1.0 million in 2023, then increased by 30.0% to $1.3 million in 2024, then rose by 15.38% to $1.5 million in 2025, then advanced by 6.67% to $1.6 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $1.6 million, $1.5 million, and $1.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.